Research programme: siRNA therapeutics - siRNAsense
Alternative Names: siRNA targeting tissue factorLatest Information Update: 27 Oct 2016
At a glance
- Originator siRNAsense
- Developer Polyplus-transfection; siRNAsense
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Cancer metastases; Prostate cancer
Highest Development Phases
- Discontinued Cancer; Malignant melanoma; Neurological disorders; Prostate cancer
Most Recent Events
- 27 Oct 2016 Discontinued - Preclinical for Cancer, Malignant melanoma, Neurological disorders and Prostate cancer in Norway as information for the products is unavailable on the company pipeline (siRNAsense pipeline, October 2016)
- 09 Oct 2013 No development reported - Preclinical for Cancer in Norway (unspecified route)
- 09 Oct 2013 No development reported - Preclinical for Malignant melanoma in Norway (unspecified route)